DCF Advisers LLC Buys New Shares in Savara Inc. $SVRA

DCF Advisers LLC bought a new position in shares of Savara Inc. (NASDAQ:SVRA) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $616,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Savara in the 2nd quarter valued at approximately $76,966,000. Deutsche Bank AG acquired a new stake in shares of Savara during the 2nd quarter worth approximately $5,328,000. Bank of New York Mellon Corp acquired a new stake in shares of Savara during the 2nd quarter worth approximately $2,294,000. Walleye Capital LLC acquired a new stake in shares of Savara during the 2nd quarter worth approximately $1,532,000. Finally, Seven Fleet Capital Management LP increased its position in shares of Savara by 371.1% during the first quarter. Seven Fleet Capital Management LP now owns 295,688 shares of the company’s stock valued at $1,614,000 after purchasing an additional 232,926 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SVRA has been the subject of a number of recent research reports. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Finally, Oppenheimer assumed coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $10.14.

Savara Stock Up 3.9%

Shares of SVRA opened at $5.58 on Thursday. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average price of $5.68 and a two-hundred day moving average price of $5.47. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -9.62 and a beta of 0.29. Savara Inc. has a 12 month low of $2.92 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities analysts predict that Savara Inc. will post -0.62 EPS for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.